Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

About the trial

Sponsor

AbbVie

Tested

Livmoniplimab (drug), Budigalimab (drug), Pembrolizumab (drug), Pemetrexed (drug), Cisplatin (drug), Carboplatin (drug), Carboplatin (drug)

Dates

Started 2024-04-10; completion 2031-10

Results posted

Not yet

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (an…

From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $933,084 in research payments for this study in 2025 (131 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.